Various Clinical Beneficial Effects for Multiple Organs by Glucagon-Like Peptide 1 Receptor Agonist (GLP-1 RA)

Bando H

Published on: 2024-10-20

Abstract

In recent clinical practice, glucagon-like peptide 1 receptor agonist (GLP-1 RA) such as semaglutide has been in focus. GLP-1 RA is known for anti-diabetic agent, and has also clinical effects for various diseased states. They include type 2 diabetes (T2D), obesity, fatty liver, heart failure, chronic kidney disease (CKD), Alzheimer disease (AD), Parkinson’s disease, addiction, depression, and others. Beneficial effects were found in recent FLOW (evaluate renal function with semaglutide once weekly) trial. Among them, semaglutide group showed beneficial results, such as lower kidney-specific outcome (HR 0.79), cardiovascular death (HR 0.71), and less steep mean annual eGFR slope (p<0.001).